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ABSTRACT The plasma membrane-cytoskeleton interface is a dynamic structure participating in a variety of cellular events.
Among the proteins involved in the direct linkage between the cytoskeleton and the plasmamembrane is the ezrin/radixin/moesin
(ERM) family. The FERM (4.1 ezrin/radixin/moesin) domain in their N-terminus contains a phosphatidylinositol 4,5 bisphosphate
(PIP2) (membrane) binding site whereas their C-terminus binds actin. In this work, our aim was to quantify the interaction of ezrin
with large unilamellar vesicles (LUVs) containingPIP2. For this purpose, weproduced human recombinant ezrin bearing a cysteine
residue at its C-terminus for subsequent labeling with Alexa488 maleimide. The functionality of labeled ezrin was checked by
comparison with that of wild-type ezrin. The afﬁnity constant between ezrin and LUVs was determined by cosedimentation assays
and ﬂuorescence correlation spectroscopy. The afﬁnity was found to be ;5 mM for PIP2-LUVs and 20- to 70-fold lower for
phosphatidylserine-LUVs. These results demonstrate, as well, that the interaction between ezrin and PIP2-LUVs is not
cooperative. Finally, we found that ezrin FERMdomain (area of;30 nm2) binding to a single PIP2 can block access to neighboring
PIP2 molecules and thus contributes to lower the accessible PIP2 concentration. In addition, no evidence exists for a clustering of
PIP2 induced by ezrin addition.
INTRODUCTION
The plasma membrane-cytoskeleton interface is a dynamic
structure, participating in a variety of cellular events including
cell shape and motility, signal transduction, and cell polar-
ization. Among the proteins involved in the linkage between
components of the cytoskeleton and the plasma membrane,
the proteins of the ezrin/radixin/moesin (ERM) family are
recognized as being important regulators in the connection
between membrane proteins and the cytoskeleton (1,2,3).
ERM proteins are organized in three distinct domains: i), the
N-terminal membrane-binding domain is shared by the ERM
proteins and by protein 4.1 and is referred to as the FERM
domain (1); ii), an a-helical domain; and iii), the C-terminal
actin-binding domain. Ezrin, one member of this family, is
largely found in intestinal microvilli and in ﬁlopodia (4).
Within the cell, ezrin can exist in two different states: either
dormant, or inactive, when the N- and C-terminal domains are
tightly associated thereby masking the F-actin and mem-
brane binding sites (via intra- or intermolecular association)
(5) or open, i.e., active, when the N-terminus is effectively ac-
cessible for membrane binding and the C-terminus is acces-
sible for actin binding (Fig. 1).
The main pathway for activation of ezrin relies on the
interaction of ezrin with phosphatidylinositol(4,5)-bisphos-
phate (PIP2) in the membrane, followed by phosphorylation
of the Thr-567 residue in the C-terminal domain, resulting in
a conformational change of the protein (1,6,7). The ﬁrst
direct evidence for ezrin binding to PIP2 came from Niggli
et al. (8), who demonstrated that the N-terminal domain of
ezrin (amino acids 1–309) was necessary and sufﬁcient for
interaction with PIP2-containing multilamellar vesicles. In
that study, it was shown that ezrin binds preferentially to
liposomes containing PIP2 as compared to other lipids such
as phosphatidylserine and that this interaction occurred at
physiological ionic strength. Under these conditions, ezrin
could discriminate between PIP2, phosphatidylinositol-4-
monophosphate, and phosphatidylserine (8). Unfortunately,
multilamellar vesicles cannot be used for quantitative
binding analysis because of their ill-deﬁned geometry.
The ﬁrst insights into the structural basis for the membrane
interaction of ERM proteins via their FERM domain came
from the study of Barret et al. (7). These authors demonstrated
that the interaction of ezrin with multilamellar vesicles and
with cell membrane was almost abolished by mutagenesis of
speciﬁc residues located in subdomains F1 and F3 of the
FERM domain. The second line of evidence came from the
determination of the x-ray crystal structure of the radixin
FERM domain complexed with IP3 (9). These results revealed
the important role of residues in a basic cleft located between
subdomains F1 and F3 (9). In addition, it was found that these
two subdomains form a relatively ﬂat molecular surface that
seems tomaximize the interactionswith themembrane surface.
In a recent study, Charras et al. demonstrated that, after
expansion of a bleb, ezrin was the ﬁrst protein recruited to
the membrane, followed by actin, actin-bundling proteins,
and, ﬁnally, contractile proteins (10). In addition to its PIP2-
dependent location at the plasma membrane, ezrin may be
itself involved in the process of membrane deformation. This
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is suggested by a recent investigation on ezrin with giant
unilamellar vesicles, where ezrin and moesin, similarly to pro-
tein 4.1, were found to open stable holes in vesicles contain-
ing an acidic lipid (11). All these ﬁndings suggest that PIP2,
which represents ;10% of all the phosphoinositides species
and ;1% of the total lipid in cell membranes (12), is an im-
portant determinant for ezrin morphogenic actions (13,14).
A useful model for investigating protein/lipid interactions
is that of large unilamellar vesicles (LUVs) because these
objects can be employed to quantitatively determine the
association constant of a given protein for a membrane.
Several more or less conventional methods are used to
achieve this goal, as reviewed by Cho et al. (15). Among
them are the quantitative cosedimentation assays using either
unlabeled protein (16), radioactive protein or ﬂuorescently
labeled protein (17), surface plasmon resonance (18), and
more recently ﬂuorescence correlation spectroscopy (19,20).
In this study, our goal was to quantify the binding of ezrin
to LUVs by means of cosedimentation assays and ﬂuores-
cence correlation spectroscopy. In particular, we wanted to
quantify the binding of ezrin to LUVs containing PIP2 in
comparison with LUVs containing other acidic lipids such as
phosphatidylserine (PS) and other phosphoinositides. We
also wanted to determine whether the binding is cooperative,
and whether PIP2 is relocalized upon binding to ezrin. The
inﬂuence of the PIP2 content in the membrane upon ezrin
binding, both at ﬁxed lipid concentration or at increased lipid
concentration were investigated. Experiments were per-
formed with either unlabeled ezrin, or an engineered ezrin
bearing a free cysteine residue labeled with Alexa488
maleimide.
MATERIALS AND METHODS
Reagents and buffer
Dimethyl sulfoxyde (DMSO) and dithiothreitol (DTT) were purchased from
Sigma (St. Louis, MO). 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphatidyl-
choline) (POPC) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylserine
(POPS) were obtained from Avanti Polar Lipids (Alabaster, AL). The
ammonium salt of L-a-phosphatidylinositol(4,5)-bisphosphate (PIP2) was
purchased from Lipid Products (Surrey, Great Britain). D-myo-phosphati-
dylinositol-4-phosphate (PI(4)P), D-myo-phosphatidylinositol-3,4-bisphos-
phate (PI(3,4)P2), and D-myo-phosphatidylinositol-3,4,5-triphosphate (PI
(3,4,5)P3), Bodipy-TMR-PI(4,5)P2, (TMR-PIP2, reference C-45M16a),
NBDC16-PIP2 (or NBD-PIP2, reference C-45N16a), Bodipy-FL-PI(4,5)P2
(Bodipy-FL-PIP2, reference C-45F16a) were purchased from Echelon
Bioscience (Tebu-Bio, Le Perray en Yvelines, France), rhodamine DHPE
from Molecular Probes (Eugene, OR) and a-methoxy-v-carboxylic acid
succinimidyl ester poly(ethylene glycol) (PEG, molecular weight of 5000)
from Nektar Therapeutics (Birmingham, AL). The MARCKS (151–175) pep-
tide was kindly provide by Prof. S. McLaughlin from Stony Brook University
(Stony Brook, NY). All buffer solutions were prepared with deionized water
(resistivity 18.2 MV/cm). Ezrin was kept at 4C in an ezrin buffer containing
70 mM NaCl, 25 mM 2-(N-morpholino)ethanesulfonic acid (MES) at pH 6.2
(MES-NaCl buffer). For the binding experiments using the cosedimentation
assay, the vesicles were prepared in a Hepes buffer containing 200 mM su-
crose, 20 mM HEPES, 0.5 mM EGTA at pH 7.4 (Hepes-sucrose buffer). All
other binding experiments (including ﬂuorescence correlation spectroscopy
(FCS) experiments) were performed in a Hepes buffer containing 100 mM
KCl, 20 mM HEPES, 0.5 mM EGTA at pH 7.4 (Hepes-KCl buffer). For
pegylation, PEGwas dissolved in sodium borate 0.1 M at pH 8.5 (borate buffer).
Protein expression and puriﬁcation
The expression and puriﬁcation of wild-type (WT) ezrin cloned in the pGEX
2-T vector have already been described (21). Ezrin has only two cysteine
residues that are indeed inaccessible. Thus, for labeling ezrin with a
ﬂuorescent maleimide derivative, an additional cysteine was added at the
C-terminal of the molecule after two extra glycine residues (GGC). The quick
change site-directed mutagenesis kit from Stratagene (Stratagene Europe,
Amsterdam, The Netherlands) was used for this purpose. Constructions were
veriﬁed by sequencing. Both wild-type ezrin and ezrin-cysteine were
obtained using the same puriﬁcation procedure. The diameter of ezrin and of
ezrin-cysteine in the MES-NaCl buffer were measured using a Malvern
nanosizer (Malvern, Worcestershire, UK).
Ezrin labeling
Labeling of ezrin-cysteine was performed using Alexa488-C5-maleimide
(Molecular Probes). Puriﬁed ezrin conserved inMES-NaCl bufferwas treated
with a 10-fold molar excess of Alexa488-C5-maleimide (dissolved in 10 ml
DMSO) for 1 h and 30 min at room temperature in ezrin buffer. The labeling
reaction was subsequently quenched by adding an excess amount of DTT and
the labeled protein was separated from the reagents using a Sephadex G25
column (GE Heathcare, France) eluted with the MES-NaCl buffer. The
labeling efﬁciency of ezrinwas estimated by determining the respectivemolar
concentration of dye and of protein (molar absorptivity ofAlexa488 at 495 nm
is e ¼ 72,000 M1 cm1 and molar absorptivity of ezrin at 280 nm is e ¼
69,000M1) and calculating the grafting ratio.Under our labeling conditions,
;0.93 mol of Alexa488 was incorporated per mol of ezrin.
Vesicle preparation
LUVs were prepared by drying the appropriate lipid mixture in a Speedvac
rotary evaporator overnight, hydrating the lipids in theHepes-KCl buffer for 2
h at 37C (interrupted by rigorous vortexing every quarter of hour), then
extruding the multilamellar vesicles through a stack of two polycarbonate
ﬁlters (100-nm pore size diameter, 21 passages) using the miniextruder from
Avanti Polar Lipids (22). LUVs were extruded and stored at high
concentration (14 mM, total lipid concentration or 7 mM accessible lipid
concentration; taking into account that only the outermost layer of the bilayer
membrane is accessible) for no more than 2 weeks. Final concentrations of
lipids were measured using the Phospholipid B kit (Wako Chemicals GmbH,
Neuss, Germany) and were within 90–95% of the expected concentration.
FIGURE 1 Scheme of the two possible conformations for ERM proteins,
(left) inactive (or closed) conformation and (right) open (or active) conforma-
tion. The three lobs represent the FERMdomain (subdomainAcomposed ofF1,
F2, and F3), the long rectangle represents the central helical region (subdomain
B), and the C-terminal domain is the actin-binding region (ellipsoid).
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j-Potential measurements
The homogeneity in size and in charge of the vesicles was checked, re-
spectively, by diffusion light scattering (DLS) and by z-potential measure-
ments on a Malvern Zeta Sizer NanoZS (Malvern). The electrophoretic
mobility of LUVs was measured at low vesicle concentration in a 50 mM
KCl, 2 mM Hepes, 0.5 mM EGTA buffer at pH 7.4 and the j-potential,
which is the electrostatic potential at the shear plane, was calculated using
the Helmholtz-Smoluchowski (Eq. 1) (23):
j ¼ uh
eRe0
; (1)
where j is the z-potential of a vesicle (in mV); u is the velocity of the vesicle
in a unit electric ﬁeld; h is the viscosity of the aqueous solution; eR is the
dielectric constant of the aqueous solution; and e0 is the permittivity of free
space. The j-potential is proportional to the surface charge density (23).
Results are given as mean 6 SD of 20 measurements on the same sample.
Cosedimentation assays
Ezrin afﬁnity for phospholipidswas determined by sedimentation assayswith
sucrose loaded LUVs. LUVs were dialyzed using a microdialyzer (Pierce,
Rockford, IL) against Hepes-KCl buffer or, when possible, theywere directly
diluted in the Hepes-KCl buffer. The cosedimentation assays were achieved
by varying the concentration of total lipids or, for a ﬁxed lipid concentration,
varying the percentage of PIP2 in the LUVs. For these experiments, ezrin
concentration was kept constant at 400 nM. In another set of experiments,
ezrin concentration was varied over a large range (from tens of nanomolars to
tens ofmicromolars) but lipid concentrationwas ﬁxed to a certain value. After
incubation for 15 min at room temperature, the 100-ml samples were
centrifuged at 223,000 3 g for 1 h at 4C using the 42.2Ti rotor (Beckman
Coulter, Roissy, France). The top 80 ml of each sample were removed and
considered as supernatant (SN); 8 ml of Triton X100 and 52 ml of KCl buffer
were added to resuspend the pellet (P). For experimentswith labeled ezrin, SN
and P intensities were directly read in a 50-ml microcuvette using the LS55
spectroﬂuorimeter (Perkin Elmer, Waltham, MA) with excitation and
emission slits set, respectively, at 488 and 519 nm (62.5 nm). Alternatively,
for experiments performed using unlabeled ezrin, SN and Pwere analyzed on
a 10% SDS-PAGE, transferred on an Immobilon-P transfer membrane
(Millipore, Molsheim, France) and the membrane stained using Coomassie
blue for quantiﬁcation. Membranes were scanned and images were analyzed
using Image J 1.36b (National Institutes of Health, Bethesda, MD) (the mean
density of each band was background corrected and we checked that band
intensities were in the linear range of the scanner). Since 20 ml of the
supernatant were counted as pellet and since the supernatant and pellet
resuspension volume were identical, the true pellet intensity was calculated
using the formula: IPellet ¼ IP  0.25ISN, where IP and ISN are the intensity of
the pellet and supernatant, respectively. The corresponding percentage of
ezrin bound was deduced (percentage of ezrin bound is IPellet / (IP1 ISN)).
Afﬁnity determination
The binding of protein to lipid bilayers can be described by deﬁning an
apparent association constant, K, as described previously (24). K is the
proportionality constant between the fraction of proteins bound to the
membrane, [Ez]B, and the molar concentration of the protein in the bulk
aqueous phase, [Ez]F.
The fraction of ezrin bound is given by:
½EzB
½EzT
¼ K½PIP2ACC
11K½PIP2ACC
; (2)
where [Ez]T is total ezrin and [PIP2]acc is the accessible PIP2 concentration.
It is assumed here, in a ﬁrst approximation, that all PIP2 on the outer leaﬂet is
accessible. The association constant K deduced from Eq. 2 is the reciprocal
of the apparent dissociation constant, which is often called the afﬁnity
constant Kd.
Fluorescence correlation
spectroscopy measurements
Fluorescence correlation spectroscopy measurements were carried out on a
two-photon FCS setup. Excitation was carried out with a tunable femtosec-
ond infrared titanium sapphire laser (MaiTai from Spectra-Physics, New-
port, Irvine, CA) set at 780 nm and 15 mW with a polarizing beamsplitter
and one-half wave-plate (Karl Lambrecht, Chicago, IL). The excitation light
was coupled to a Zeiss (Jena, Germany) Axiovert 200 M microscope,
reﬂected by a Chroma (Rockingham, VT) 700DCSXR dichroic mirror, and
focused onto the sample with a Zeiss Apochromat 633 1.4 NA immersion
objective. Emitted photons were detected through an infrared blocking ﬁlter
(Chroma 700SP) with a dual channel ISS ALBA ﬂuorescence correlation
detector with avalanche photodiodes, with a Chroma Q565LP dichroic
mirror to separate the red and green emissions, and a Chroma HQ610/75 and
HQ525/50 bandpass ﬁlter for the two channels (rhodamine and Alexa 488,
respectively). To prevent nonspeciﬁc adsorption of ezrin, PEGylation of the
glass slide (thickness 170 mm) was performed following a protocol that has
been described elsewhere (25) using Vectabond in a ﬁrst step and PEG-
succinimidyl ester in a second step. A silicone insulator (P24742, Molecular
Probes) glued to the glass slides was used to prepare several wells, which
were ﬁlled with 10 ml of sample. For all the FCS measurements, 10 ml of
sample was deposited in each well. For the ezrin/LUVs interactions studies,
ezrin-Alexa488 was used because Alexa488 is an excellent ﬂuorophore for
FCS measurements: it has low triplet state excitation, a high quantum yield,
and high photostability (26). Also, attaching a rather hydrophilic ﬂuorophore
should not signiﬁcantly affect the molar partition coefﬁcient of the protein,
in contrast to what was observed for hydrophobic ﬂuorescent probes (like
Texas red) attached to small peptides (27). For each experimental condition,
the ﬂuorescence ﬂuctuation signal (i.e., the ﬂuorescence signal detected in
the small open volume deﬁned by two-photon excitation probability) was
measured at seven different locations in each well, for the labeled protein
alone (15 nM) and for samples containing ezrin in contact with LUVs at
increasing lipid concentration. The intensity ﬂuctuations are time correlated
to generate an autocorrelation function G(t), deﬁned as:
GðtÞ ¼ ÆdFðtÞdFðt1 tÞæ
ÆFðtÞæ2 ; (3)
with t being the lag time. Generally the ﬂuorescence ﬂuctuations can be
considered to arise from concentration ﬂuctuations within the effective
volume, and a translational diffusion time, td, can be extracted from the
autocorrelation proﬁle:
GðtÞ ¼ 1
N
11
t
td
 1
11
r
2
ot
z2otd
 12
; (4)
where N is the average number of molecules in the observation volume, and
r0 and z0 the waist and height of the volume that are given by the three-
dimensional Gaussian expression for the intensity proﬁle:
Vpsf ¼ p
2
 3
2ðr2ozoÞ: (5)
The effective volume was calibrated from measurements using 60 nM
ﬂuorescein assuming a diffusion coefﬁcient 300 mm2/s in terms of the
volume derived from the intensity proﬁle (the point-spread function), Vpsf,
such that:
Gð0Þ ¼ g
ÆCæVpsf
; (6)
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where ÆCæ is the mean concentration of molecules and g a factor. It provides
a measure of the uniformity of the ﬂuorescence intensity observed for
molecules at different positions within the volume and the abruptness of the
boundaries. Its value is taken to be ;0.7.
In the case of the ezrin/LUVs system, the autocorrelation function can be
analyzed in terms of the diffusion times of the bound and free species, and
their respective fractional populations.
GðtÞ ¼ 1
N
Ff 11
t
tdf
 1
11
r
2
ot
z
2
otdf
 1
2
 ! 
1 Fb 11
t
tdb
 1
11
r
2
ot
z
2
otdb
 1
2
 !!
; (7)
where Ff and Fb are the fractions of the free and bound species, respectively,
and tdf and tdb their respective diffusion times. Data analysis was performed
with the ISS Vista software. This program uses a Marquardt-Levenberg
minimization algorithm and the goodness of the ﬁttings can be judged by the
recovered x2. The series of autocorrelation curves were pooled (one curve
for each lipid concentration) and were globally analyzed (linked analysis)
with two diffusion coefﬁcients (one for the free protein, one for the bound
protein) (28). This analysis yielded the percentage of bound ezrin, which
was ﬁnally plotted as a function of the total accessible PIP2 concentration for
determination of the dissociation constant (Eq. 2). All experiments were
performed at least three times with different LUVs and ezrin preparations.
Fluorescence quenching experiments
Self-quenching was measured using the LS55 spectroﬂuorimeter (Perkin
Elmer, Courtaboeuf, France). Two different probes (NDB, excitation 472
nm/emission 529 nm, and Bodipy-TMR, excitation 547 nm/emission 570
nm) were used. The emission intensities were collected as unlabeled ezrin
was added to the solution containing the LUVs. The following equation was
used to calculate the percentage of quenching:
% of quenching ¼

1 IP
I0

3 100; (8)
where Ip is the intensity of ﬂuorescence emitted from labeled LUVs in the
presence of ezrin, and I0 is the intensity of ﬂuorescence emitted from labeled
LUVs in the absence of ezrin. The quenching experiments were performed
with vesicles containing ﬂuorescent lipids present at the maximal molar
fractions that did not exhibit appreciable self-quenching (4% for NBD lipids
and 1% for Bodipy-TMR PIP2 in the LUVs). This amount of self-quenching
due to the proximity of neighboring NBD lipids was determined by com-
paring the ﬂuorescence intensity of LUVs containing increasing percentages
of NBD lipids (from 0 to 6% of NBD-PC) and of the same lipids after
perturbation of the LUVsmembrane by addition of 1%TritonX100. The total
lipid concentration was 40 mM for 99:1 PC/TMR-PIP2 and 30 mM for 96:4
PC/NBD-PIP2 LUVs, respectively. These concentrations are sufﬁciently high
to bind up to 70% of PIP2 when ezrin concentration is;6 mM.
RESULTS
Preparation of LUVs containing various
amounts of PI(4,5)P2 and containing
other phosphoinositides
The homogeneity in size and in charge of the vesicles was
checked, respectively, by diffusion light scattering measure-
ments (data not shown) and by z-potential measurements. As
PIP2 is highly negatively charged, the lowering in the
z-potential was measured when PIP2 concentration is
increased in the LUVs. The z-potential of LUVs containing
an increasing percentage of PIP2 is shown in Fig. 2. It
steadily decreases when the mass percentage of PIP2 is
increased, suggesting a uniform distribution of PIP2 in the
vesicles for the different preparations. This is a proof for the
effective incorporation of PIP2 in the LUVs in proportion to
the percentage initially incorporated in the lipid mixture
before the dehydration step. Indeed, the effective incorpo-
ration of the other phosphoinositides (respectively PI(4)P,
PI(3,4)P2, and PI(3,4,5)P3) and of PS was conﬁrmed by
z-potential measurements on LUVs containing either 5% of
the phosphoinositides and 20% of PS (see Table 2). As ex-
pected based on the molecular structures of the phosphoinosi-
tides headgroups, the z-potentials are in the order PI(3,4,5)P3,
PI(3,4)P2 ; PIP2 , PI(4)P and LUVs containing 5% of PIP2
are slightly less negative than those containing 20% of PS
(24.5 mV as compared to27.7 mV). This is in agreement
with previous reports on z-potential of multilamellar vesicles
containing PS (29) and PIP2 (30).
Quantiﬁcation of ezrin binding to PIP2 using
cosedimentation assays
We determined the dissociation constant, expressed in terms
of accessible acidic phospholipid (Kd), for the interaction
between ezrin and LUVs of varying acidic phospholipid
content. In a ﬁrst set of experiments, quantitative cosedi-
mentation assays on ezrin were performed. The concentra-
tion of protein (400 nM) was chosen to ensure: i), that the
binding sites on the LUVs were not saturated; ii), that the
ratio of protein to lipids is low; and iii), that the detection
FIGURE 2 z-Potential of unilamellar vesicles as a function of the mass
percentage of PIP2 in the LUVs. The electrophoretic mobility of the LUVs
was measured and the z-potential was calculated according to Eq. 1. The 6
SEs are calculated from 20 measurements on each sample.
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levels on stained membranes or via spectroﬂuorimetry were
adequate. The experiments were performed with LUVs
composed of phosphatidyl choline (PC) and the acidic
phospholipid PIP2 or phosphatidyl serine (PS), PIP2 having a
higher negative charge per molecule than PS (about 3 for
PIP2 versus 1 for PS (30)). For WT ezrin, supernatant, and
pellets were analyzed by SDS-PAGE followed by transfer on
membranes, staining, and subsequent image analysis. Typ-
ical images of membranes representing the pellets and the
supernatants of the PC/PIP2 LUVs (95:5) that have been
cosedimented with ezrin (400 nM) are shown in Fig. 3 A for
increasing accessible lipid concentration (from 10 mM to 2.2
mM). In Fig. 3 B, the percentage of ezrin bound is repre-
sented as a function of the accessible acidic lipid concen-
tration for LUVs containing either PIP2 at 5% or PS at 20%.
For comparison, LUVs made of pure PC are also shown. The
binding of ezrin to LUVs increases when the concentration
of LUVs is increased. The ﬁt of the experimental data using
Eq. 2 leads to Kd ¼ 5.9 6 0.7 mM for LUVs containing 5%
PIP2 and 47.3 6 8.3 mM for LUVs containing 20% PS,
which is an approximately eightfold lower afﬁnity (Table 1).
Ezrin interaction with PC LUVs is negligible.
Ezrin-cysteine was used as well for analysis on membranes
and results show that both type of ezrin present similar
behavior, which indicated the mutation does not interfere with
the binding of ezrin to the vesicles (see Supplementary Fig.
S1). The binding of ezrin-Alexa488 to LUVs as measured
by the cosedimentation assay followed by spectroﬂuorimetry
analysis is represented in Fig. 4. By this method, we found
that ezrin-Alexa488 binds to LUVs composed of PC and 5%
PIP2 with Kd ¼ 4.06 0.5 mM and to LUVs composed of PC
and 20% PS with Kd¼ 63.8 6 10.5 mM, which is ;16-fold
lower afﬁnity (Table 1). Thus, WT ezrin and ezrin-Alexa488
were found to behave similarly as these data are in good
agreement with those obtained by cosedimentation and anal-
ysis on membrane. This also quantitatively conﬁrms the pre-
vious ﬁnding that ezrin has binding speciﬁcity for PIP2 over
PS (8).
Ezrin LUV interactions by ﬂuorescence
correlation spectroscopy
Recently, ﬂuorescence correlation spectroscopy was em-
ployed to analyze the binding of MARCKS 151–175 to
LUVs (20). The results obtained for this peptide were
comparable to those obtained from binding measurements of
radioactively labeled MARCKS 151–175 using a centrifu-
gation technique. It was also used by Takakuwa et al., who
investigated the binding of protein 4.1 (molecular mass, 80
kDa) with LUVs containing PS at different percentages (19).
The principle of the measurement relies on the fact that
LUVs and proteins, which have signiﬁcantly different sizes,
will have two distinct diffusion coefﬁcients that will give rise
to two correlation times (28).
In our case, we ﬁrst we measured the diffusion coefﬁcient
of ezrin-Alexa488 and of LUVs containing 0.01% of DHPE-
rhodamine (Fig. 5 A). The diffusion coefﬁcient of LUVs was
found to be of;3 mm2/s and that of ezrin of;55 mm2/s, i.e.,
;15-fold higher. This is in agreement with the value of 4
mm2/s and 58 mm2/s, respectively, for LUVs and ezrin,
which can be estimated using the Stokes-Einstein equation
(taking 7.5 nm for the measured ezrin diameter and 100 nm
for the LUVs diameter, h ¼ 0.89 mPa s for the viscosity of a
100 mM KCl solution at 25C).
Following the protocol described by Rusu et al. (20), we
prepared solutions containing ezrin at a ﬁxed concentration
(typically 15 nM) and increased concentration of LUVs while
keeping the fraction of PIP2 constant. Fig. 5 B shows
autocorrelation curves for experiments where ezrin-Alexa488
was in LUVs solution containing increasing lipid concen-
tration (from 10 mM to 1 mM accessible lipid). The auto-
correlation curve on the left represents the case when all
ezrin molecules are free. The population of bound ezrin
FIGURE 3 Binding of wild-type ezrin to LUVs as measured by the
cosedimentation assay. Pellet and supernatants were migrated on gels and
then transferred to membranes, stained with Coomassie blue for visualiza-
tion and quantiﬁcation. (A) Images of the membranes corresponding to the
binding of ezrin to 95:5 PC/PIP2 LUVs (from left to right, increasing
accessible lipid concentration from 10 mM to 2.2 mM); P corresponds to the
pellet and SN to the supernatant. Ezrin was kept constant at 400 nM. (B) The
percentage of ezrin bound is represented at different acidic lipid concen-
trations (s) (PC/PIP2, 95:5), x axis is the PIP2acc concentration; (h) (PC/
PS, 80:20), x axis is the PSacc concentration; (=), PC 100%, x axis is the
accessible lipid concentration. The curves are the least squares ﬁts of Eq. 2 to
the data, which yield the value for the molar partition coefﬁcient K from
which the afﬁnity constant Kd (Kd ¼ 1/K) can be deduced (points are mean
6 SD of three independent experiments).
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grows as the lipid concentration increases as observed by the
shift of the autocorrelation functions to longer timescales.
Data analysis yielded the percentage of bound ezrin from left
to right, as 0%, 3%, 15%, 26%, 47%, 61%, and 99%,
respectively. Fig. 6 shows the percentage of ezrin bound to
either PC/5%PIP2, PC/20%PS, or PC vesicles as a function
of the accessible acidic lipid concentration. The curves are
the least-square ﬁts of Eq. 2 to the data. Ezrin binds more
strongly to vesicles containing PIP2 (Kd ¼ 6.2 6 0.8 mM)
than to those containing PS (Kd ¼ 5806 57 mM), i.e., ;90-
fold lower and barely binds to PC LUVs. It should be noted
that experiments performed at 15 and 45 nM ezrin concen-
tration lead to similar results. In Table 1, the afﬁnity
constants deduced from these ﬁtted data are compared to
those from the cosedimentation assays. The data agree well
in particular for the Kd values estimated for the PIP2
containing vesicles. However, the nonspeciﬁc (electrostatic)
binding of ezrin to PS containing LUVs is apparently lower
when measured by FCS. Indeed, it was reported that the
charge and size of the vesicles may signiﬁcantly affect the
efﬁciency of the cosedimentation assays due to vesicle
nonspeciﬁc aggregation (15). This may explain why the
TABLE 1 Dissociation constants (Kd) expressed in terms of accessible acidic phosphospholipid (mean of three independent
experiments 6 SD) and measured by three different types of assay
Lipid
composition
Cosedimentation
using WT ezrin
(membrane staining)
Cosedimentation
using ezrin-Alexa488
(spectroﬂuorimetry)
Fluorescence
correlation
spectroscopy
Kd (mM) Increase in
Kd (fold)
Kd (mM) Increase in
Kd (fold)
Kd (mM) Increase in
Kd (fold)
5% PIP2 5.9 6 0.7 1 4.0 6 0.5 1 6.2 6 0.8 1
20% PS 47.3 6 8.3 8 63.8 6 10.5 16 580 6 57 94
20% PS/5% PIP2 NA – 4.2 6 0.4 1.1 3.3 6 0.8 0.5
FIGURE 4 Binding of ezrin-Alexa488 to LUVs as measured by the cosed-
imentation assay followed by spectroﬂuorimetric analysis. The ﬂuorescence of
the pellet and supernatants were measured at excitation 488 nm and emission
519 nm. The percentage of ezrin bound is represented at different acidic lipid
concentrations (s) (PC/PIP2, 95:5), x axis is the PIP2acc concentration; (h)
(PC/PS, 80:20), x axis is the PSacc concentration. The curves are the least
squares ﬁts of Eq. 2 to the data, which yield the value for the molar partition
coefﬁcient K (points are mean 6 SD of two independent experiments). Ezrin
was kept constant at 400 nM. Note the similarity with Fig. 3.
FIGURE 5 FCS measurements of ezrin, LUVs, and ezrin binding to PC/
PIP2 (95:5) LUVs. (A) Autocorrelation curves of ezrin-Alexa488 (d) and
rhodamine DHPE-labeled LUVs (h), which have a diameter of 100 nm. The
diffusion coefﬁcient was ;55 mm2/s for ezrin and ;3 mm2/s for the LUVs.
(B) Autocorrelation curves obtained from a solution containing 15 nM ezrin-
Alexa488 and different lipid concentrations are shown. Autocorrelation
curves from left to right are shown for 5 mM to 1 mM accessible lipid con-
centrations, corresponding to 0% (3), 3% (s), 15% (=), 26% (¤), 47% (n),
61% (n), and 99% (s) ezrin bound, respectively. The lines represent the best
ﬁt of the two-component model, Eq. 7.
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percentage of ezrin bound to PC/20% PS LUVs is system-
atically higher when measured by the cosedimentation
assays.
Phosphoinositide speciﬁcity of ezrin and role of
PS and cholesterol in the binding
We next measured the effective dissociation constant of
ezrin-A488 for LUVs containing different phosphoinositides
using the quantitative cosedimentation assay and FCS to
investigate the selectivity of ezrin for phosphoinositides. All
the results are summarized in Table 2. The comparison of the
binding of various phosphoinositides to ezrin indicates that
ezrin has modest selectivity for PI(4,5)P2 (Table 2). The Kd is
of the same order of magnitude for PIP2 and PI(3,4,5)P3 and
is at least three- to ﬁvefold lower for vesicles containing
PI(3,4)P2 or the monophosphorylated phosphoinositide
PI(4)P. However, the ﬁnding that ezrin’s afﬁnity for LUVs
is about the same for PIP2 (z-potential of 24.5 mV) and for
the more anionic PI(3,4,5)P3 (z-potential of 30.5 mV) as
compared to the similarly charged PS LUVs (z-potential of
27.7 mV) conﬁrms that the observed selectivity does not
originate simply from nonspeciﬁc electrostatic interactions.
The presence of two phosphate groups also seems to be
important.
Recently, Hokanson et al. suggested that low concentrations
of PS might contribute to the binding energy when myo1C
is attached to the membrane via phosphoinositides (31). In
another study, Gokhale et al. (32) found that Annexin 2t
showed no detectable afﬁnity for a membrane that contained
3 mol % PIP2 but without cholesterol. In our case, no de-
tectable inﬂuence of a mixture of PS/PIP2 nor of cholesterol
could be observed (Table 2).
Ezrin binding to PIP2 is not cooperative
An important question remains concerning the possible
existence of cooperativity in the ezrin binding to the PIP2
containing LUVs. The assay for probing this question
differed from the previous ones in that total lipid concen-
tration (and thus LUVs concentration) was held constant and
only the mass fraction of PIP2 was varied. We measured the
binding of ezrin to 0.14 mM accessible total lipid composed
of 0–15% PIP2 while holding the total lipid concentration
constant (Fig. 7). A monotonic increase can be observed in
the binding curve, not a sigmoidal shape. Therefore, the
hyperbolic dependence of ezrin binding on the percentage of
PIP2 was ﬁtted using Eq. 2, which gave an apparent Kd of
2.36 0.3 mM. Also, when the data are plotted as ezrin bound
versus the accessible PIP2 concentration, the percentage of
binding for 100 mM LUVs composed of 0–15% PIP2 and
for LUVs composed of 5% PIP2 measured at different to-
tal lipid concentrations are similar (Fig. 7, inset, data for 5%
PIP2 are taken from Fig. 4). Therefore, the interaction of ezrin
with PIP2 is not cooperative, but rather has a 1:1 binding
stochiometry.
FIGURE 6 FCS measurements of ezrin binding to PC/PIP2, PC/PS, and
PC LUVs (ezrin-Alexa 488 at 15 nM). The percentage of ezrin bound,
deduced from data similar to those illustrated in Fig. 5 is plotted as a function
of the accessible lipid concentration for (s) (PC/PIP2, 95:5), x axis being the
PIP2acc concentration; (h) (PC/PS, 80:20), x axis being the PSacc con-
centration; and (=) PC vesicles. The curves are the least squares ﬁts of Eq. 2
to the data. Points are mean 6 SD of seven measurements on each sample.
TABLE 2 Dissociation constants (Kd) expressed in terms of accessible acidic phosphospholipid (mean of two independent
experiments 6 SD) and measured by the cosedimentation assay using ezrin-Alexa488 or by ﬂuorescence correlation spectroscopy
z-potential
(mV)
Kd (mM)
Cosedimentation
Increase in
Kd (fold)
Kd (mM)
FCS
Increase
in Kd (fold)
Cellular
abundance (of
all PI species)
20% PS 27.7 6 1.8 63.8 6 10.5 16 580 6 57 94 –
PI(4,5)P2 24.5 6 0.5 4.0 6 0.5 1 6.2 6 0.8 1 ;10%*
5% PIP2 NA 4.2 6 0.4 1.1 3.3 6 0.8 0.5
20% PS/5% PIP2 NA 4.1 6 0.5 1.0 NA –
15% chol/5% PIP2
5% PI(4)P 17.6 6 1.6 13.1 6 0.6 3.3 31.5 6 9.4 5.1 ;10%*
5% PI(3,4)P2 25.6 6 1.2 5.3 6 0.7 1.3 23.5 6 5.6 3.8 ,0.15%
5% PI(3,4,5)P3 30.5 6 1.5 5.6 6 0.7 1.4 9.6 6 1.1 1.5 ,0.15%
The z-potential of the LUVs is also given; NA, not available.
*Values taken from Pendaries et al. (62).
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Ezrin does not induce the clustering of PIP2
We then sought to investigate whether the binding of ezrin is
able to cluster PIP2 molecules. Experimentally, we checked
whether ezrin can produce self-quenching of NBD-labeled
LUVs when the ﬂuorescent lipid is present in the vesicles at a
concentration just below the level that produced self-
quenching. In a ﬁrst step, it is thus necessary to determine
the percentage at which self-quenching begins to occur in
LUVs. We found for NBD-PC LUVs that self-quenching
occurs at percentage above 4% (Supplementary Fig. S2).
Unfortunately, in this control experiment, NBD-PIP2 could
not be employed as we found that a strong quenching
occurred upon disruption of the LUVs with 1% TrixonX-
100. This quenching can presumably be attributed to the
micelle forming capacity of PIP2 (and of NBD-PIP2 in
solution) as already evidenced in the past (33). As a
consequence, if we assume a similar behavior for NBD-PIP2,
even a small redistribution of PIP2 in vesicles containing 4%
NBD-labeled PIP2 should increase self-quenching. Thus, the
percentage of self-quenching of NBD-PIP2 was measured for
different ezrin concentrations and calculated according to
Eq. 8. We found that ezrin did not induce self-quenching
when it binds to the LUVs (Supplementary Fig. S2). This
was conﬁrmed using Bodipy-FL-PIP2 instead of TMR-PIP2.
As a control experiment, we veriﬁed that MARCKS is
effectively inducing the quenching of TMR-PIP2 in LUVs,
as already shown in previous experiments (27,34). This
quenching experiment suggests that ezrin does not sequester
PIP2 in the membrane. When PC/1% TMR-PIP2 LUVs were
used (1% being the maximal fraction that does not exhibit
self-quenching (27), results were qualitatively similar and no
self-quenching occurred (data not shown).
Ezrin binding may contribute to mask underlying
PIP2 molecules not engaged in the interaction
when PIP2 concentration in the LUVs is high
We next investigated the inﬂuence of ezrin concentration for
a given accessible lipid concentration (thus also LUVs
concentration) on the total amount of ezrin bound to LUVs
containing various percentages of PIP2 (Fig. 8). This kind of
experiment allows one to investigate the possibility for a
restricted access to PIP2 targets, as one ezrin binds one PIP2
molecule. Due to the anisotropic shape and large area of the
FERM domain (Figs. 9 and 10), ezrin may mask other PIP2
molecules that would be inaccessible. Thus, when plotted in
terms of ezrin bound for different percentages of PIP2 in the
LUVs, this phenomenon should lead to saturation in the
amount of ezrin bound. In this experiment, the accessible
lipid concentration was set at a high value (0.88 mM, which
is equivalent to a LUVs concentration of 14.2 nM) so that the
vesicle concentration itself was not the limiting factor, but
rather the percentage of PIP2 The total amount of ezrin
bound is represented as a function of the initial ezrin
concentration, for LUVs containing either 1%, 5%, or 7.5%
of PIP2 (Fig. 8). The amount of ezrin bound shows a steep
increase for the 1% PIP2 concentration and levels off very
rapidly when ezrin concentration reaches 4 mM. This
indicates that all the binding sites are presumably saturated.
On the other hand, the amount of ezrin bound steadily
increases for LUVs composed of 5% PIP2 concentration and
does not reach a plateau over the range of concentrations
investigated, which indicates that there are still available
FIGURE 7 Binding of ezrin to LUVs for increasing PIP2 concentrations.
Binding of 400 nM ezrin-Alexa488 to 0.14 mM LUVs (accessible lipid)
composed of 0–15% PIP2 as measured by the cosedimentation assays
followed by spectroﬂuorimetric analysis. The percent of ezrin bound is
plotted as a function of the percentage of PIP2 in the LUVs rather than total
lipid concentration. Each point is the average of three experiments. The
curve is the best ﬁt with Kd ¼ 2.3 6 0.3 mM. (Inset) Data in inset are
represented as a function of accessible [PIP2] concentration and also include
the data from Fig. 4 (d). The solid line is the best ﬁt of all the data yielding
Kd ¼ 2.7 6 0.3 mM.
FIGURE 8 Amount of ezrin-Alexa488 bound to 0.88 mM LUVs (acces-
sible lipid) as a function of the initial concentration of ezrin, as measured by the
spectroﬂuorimetric cosedimentation assay for LUVs containing 1% PIP2 (s),
5% PIP2 (d), and 7.5% PIP2 (=).
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binding sites for ezrin. The LUVs containing 7.5% of PIP2
have a very similar behavior to that containing 5% of PIP2.
Thus, it seems that the maximal amount of ezrin bound is
reached when the percentage of PIP2 is ;5–7.5%. We
suggest that this inaccessibility is due to the large size of
ezrin FERM domain, which is ‘‘masking’’ PIP2 molecules.
The range of values obtained here are in qualitative
agreement with the values obtained in Fig. 7 at lower ezrin
concentration and lower LUVs concentration. To verify this
hypothesis, we performed a simple calculation based on the
known percentage of PIP2 in the LUVs. We calculated the
mean distance between two neighboring PIP2 molecules
(dmin) according to Eq. 9, knowing the mass % of PIP2 in the
spherical membrane, the surface area of PIP2 molecules esti-
mated at 1.1 nm2 (33), the surface area of PC molecules esti-
mated at 0.7 nm2, and the molar mass of PC and PIP2 (Fig. 9).
dmin ¼ 2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1:1½%PIP21 0:7ð100%PIP2Þ
p3 ½%PIP2
s
: (9)
It should be noted that we assumed here that PIP2
molecules are not clustered in the membrane because: i),
PIP2 has a net negative charge estimated at 3 (30), and ii),
recent experimental evidence suggests that PIP2 alone does
not form domains when incorporated in PC membrane (35);
dmin rapidly decreases when the percentage of PIP2 in-
creases. In Fig. 9 B, we present a schematic of the interaction
between the FERM domain of ezrin with PIP2 molecules, for
PIP2 concentrations of, respectively, 2% and 7% (corre-
sponding to dmin ; 7 nm and dmin ; 3.5 nm, respectively).
For this purpose, and according to the structural predictions
of Hamada (9) for radixin (radixin and ezrin have 90%
identity sequence), the ezrin FERM domain was approxi-
mated to an ellipse of axes 3.1 and 6.5 nm (distances were
measured with SPDB-viewer, leading to an area of ;30
nm2). This schematic shows that many PIP2 molecules are
inaccessible when the concentration of PIP2 is high. As a
consequence, for high PIP2 concentrations, the true acces-
sible PIP2 concentration may be much lower than the PIP2
concentration initially introduced in LUVs. This is in
agreement with the results of Fig. 8.
DISCUSSION
Comparison with afﬁnities of other proteins
for PIP2
The Kd value for interaction with PIP2-LUVs (;5 mM) is on
the same order of magnitude to that of other membrane-
associated proteins such as a fragment from N-WASP (36),
talin (37), higher than for the PH-homology domain in
FIGURE 9 (A) Mean distance between two PIP2 mole-
cules (dmin) as a function of the percentage of PIP2 in the
LUVs. (B) Schematic of the interaction of the FERM
domain of ezrin with PIP2 molecules (represented by black
dots), when PIP2 concentration in the LUVs is set at 2%
(left) and at 7% (right). (The FERM domain can be
approximated to an ellipse with short and long axes of,
respectively, 3.1 and 6.5 nm). This clearly shows that many
PIP2 molecules are inaccessible when the concentration of
PIP2 is high.
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b-spectrin (Kd ; 40 mM (38), but one order of magnitude
lower than that of myosin 1c (31,39) and of annexin 2 (32). It
is also two orders of magnitude lower than that of MARCKS
(Kd ; 0.01 mM (20)). It has to be noted that, in the case of
annexin 2, Kd was measured using surface plasmon reso-
nance on LUVs adsorbed to the sensor chip. This different
conﬁguration may lead to different Kd values. In our case, we
found that Kd estimated by surface plasmon resonance for 2%
PIP2-LUVS was one order of magnitude lower (;0.4 mM)
than that found by spectroﬂuorimetry and by FCS (data not
shown). In the case of surface adsorbed LUVs, it is difﬁcult
to estimate the true PIP2 concentration due to the vesicles
immobilization.
Nonclustering of PIP2 upon interaction with ezrin
PIP2 has several important roles in vivo and it was
hypothesized that it is concentrated in membrane micro-
domains, such as cholesterol-rich lipid rafts (40,41). Also,
some in vitro studies suggest that it may exist in clusters (or
is locally sequestered) when bound to proteins (32,34).
According to Janmey et al. (41), three possible mechanisms
could explain this clustering: i), local membrane curvature
because PIP2 is a micelle-forming lipid that prefers curved
surfaces instead of ﬂat membrane (33); ii), presence of
hydrogen bonds between adjacent PIP2 molecules and water
bridging; iii), interactions with cytosolic proteins, or periph-
eral membrane-bound proteins or transmembrane receptors
that contain a PIP2 binding site (usually a basic domain).
There are now several proofs of evidence that PIP2 does
not by itself form domains when incorporated into model
membranes. Atomic force microscopy observations on
POPC supported lipid bilayers containing PIP2 showed a
uniform distribution of the lipids (42). Similar results were
found on LUVs using ﬂuorescence measurements on 5%
NBD-PIP2-containing POPC membrane (35) (they contra-
dict another study performed by Gericke et al. (43) on LUVs
but in this latter case, the acyl chain of the labeled PIP2 was
much shorter (C6), which may explain the poor incorpora-
tion in the lipid membrane). The situation is different when
PIP2 in the vesicle is interacting with proteins. Using a
similar quenching assay, McLaughlin and co-workers
(27,44) evidenced that the polybasic effector domain of
MARCKS forms clusters of PIP2 in LUVs. Recently,
annexin 2t was also found to induce PIP2 clustering in
both LUVs (by observing a shift in the ﬂuorescence emission
of Laurdan) and GUVs (by using PIP2-labeled GUVs and
labeled annexin 2t) (32). It has indeed been suggested, in the
case of A2t, that the lateral interaction between proteins may
increase PIP2 clustering. On the other hand, other proteins,
like annexin 2 and the PH domain of PLCd1, were found not
to cluster PIP2 (32). Our data with ezrin suggest that PIP2 in
LUVs is not forming domains upon ezrin interaction.
The 1:1 stoichiometry of ezrin/PIP2 binding presumably
indicates that ezrin has only one interaction site with PIP2. In
fact, x-ray crystallography data on radixin and moesin show
that the FERM domain is organized in a cloverleaf structure
containing three lobs (F1, F2, F3) (9,45). F1 and F3 are
forming a molecularly ﬂat surface that is positively charged
and contains several basic residues (Fig. 10). According to
the structure of the complex inositol-(1,4,5)-trisphosphate
(IP3) with the radixin FERM domain, a basic cleft containing
many lysine and arginine residues (Fig. 10, residues colored
in blue and green), located between F1 and F3 subdomains,
is responsible for a stereospeciﬁc interaction (9). At the same
time, site-directed mutagenesis on ezrin allowed Barret et al.
(7) to identify three pairs of lysine residues that are necessary
for PIP2-membrane binding (K62,K63 in subdomain F1, and
K253, K254, K262, K263 in F3; Fig. 10, residues colored in
orange). This led Balla et al. to hypothesize that there are
two potential PIP2 binding sites (46). However, by looking at
the surface of the FERM domain (Fig. 10 C), we rather
suggest that all the amino acids are important in the ezrin/
PIP2 binding and contribute to stabilize the interaction.
Biological relevance of
ezrin/phosphoinositides binding
Our results suggest that ezrin binds PIP2-containing mem-
brane with a moderate afﬁnity (Kd ; 5 mM) and that this
FIGURE 10 (A) Primary sequences of ezrin in the
subdomains F1 and F3 of the FERM domain, where
potential PIP2 and IP3 binding sites have been localized
(Protein Data Bank code, 1GC6). Potential binding site in
ezrin as identiﬁed by Barret et al. (7) who performed site-
directed mutagenesis on three lysine pairs (K63, K64; K253,
K254; K262, K263) are indicated in orange. The basic
residues (K278 in green and R273, R275, R279 in blue)
being part of the basic cleft, according to Hamada et al. (9)
are also indicated. In italic are the arginine and lysine
residues from the basic cleft but that are not on the surface of
the FERM domain. (B) Three-dimensional visualization of
the FERM domain (lateral view) by SPDB-Viewer 3.7. (C)
A slab of 10 A˚ in the direction of the arrowhead, allowing
one to visualize the molecularly ﬂat surface of the FERM
domain.
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interaction is speciﬁc. Ezrin has modest selectivity for PIP2
and binds equally well to PI(3,4,5)P3. However, in the cell in
the resting state, PIP2 accounts for 99% of all the PI lipids
whereas PI(3,4,5)P3 has only transient localized peaks
during events such as chemotaxis (47), (48), macropinocy-
tosis (a non-clathrin-mediated endocytotic pathway (49)), or
phagocytosis (50). In phagosomal membrane, PI(4)P is the
most abundant phosphoinositide produced, followed by
PIP2, whereas PI(3,4,5)P3 is detected only occasionally (51).
Indeed, actin assembly on phagosomes was found to require
PIP2/ezrin interactions.
Events such as endocytosis and phagocytosis, if they
disorganize the membrane-cytoskeleton architecture locally,
do not seem to alter the general distribution of ezrin (52,53).
But Araki et al. (49) suggested that proteins that can bind to
both PIP2 and PI(3,4,5)P3 may be associated with macro-
pinosomes longer than proteins that can bind only to PI(4,5)P2.
Thus, ezrin would fall in this category, although it has never
directly been shown to interact with PI(3,4,5)P3 in vivo.
Interestingly, in epithelial cells, PI(3,4,5)P3 was recently
found to be localized mainly on the basolateral membrane
(54), whereas ezrin is enriched at the apical surface (55). Thus,
the cellular localization of ezrin may well depend on the
associated proteins in addition to speciﬁc phosphoinositides.
Ezrin/PIP2 interactions in mediating
cytoskeletal changes
PIP2 is highly concentrated in actin-rich structures, where it
regulates the activity of actin polymerization/depolymeriza-
tion via gelsolin, N-WASP, or proﬁlin (56). In fact, actin is
negatively charged at pH 7.4 (pI ¼ 5.6) and each actin
monomer bears an excess of four negative charges (57). Thus,
actin is not expected to directly bind the negatively charged
PIP2. On the contrary, a number of actin-binding proteins such
as ERM proteins (vinculin, talin, actinin, gelsolin, or proﬁlin)
bind PIP2. The ﬁnal cellular effects of these proteins (actin
bundling, (de)polymerization, or stabilization) and the varia-
tions in the PIP2 concentration, will depend on the balance
between their relative amount and their cellular localization.
PIP2 is also known to regulate the adhesion energy
between the cytoskeleton and the plasma membrane (58).
Based on measurement of the adhesion energy between the
plasma membrane and the cytoskeleton, Nebl et al. (59)
suggest that there are several thousands of PIP2 molecules
permm2, each capable of binding with low afﬁnity membrane-
associated proteins. They hypothesize that large regions of
eukaryotic cell surfaces are supported by either large numbers
of low afﬁnity interactions (i.e., very dynamic interactions)
or by few, sparsely distributed high afﬁnity interactions. In
the ﬁrst case, these interactions, although of weak afﬁnity,
would be cumulatively important and sufﬁcient for many
cellular processes.
A simple calculation allows one to estimate that, in a cell
of 10 mm in diameter, a typical PIP2 concentration of 1% has
an effective concentration of ;15 mM on the membrane
surface (60,61), which would be sufﬁcient to fully activate
ezrin. In addition, cellular speciﬁcity of ezrin for PIP2 would
derive from a combination of modest PIP2 selectivity (Table
2) and the relative abundance of PIP2 over other phospho-
inositides (62). Thus, ezrin-PIP2 interaction at the inner
plasma membrane may serve to concentrate ezrin at regions
where other proteins that can bind ezrin will come into play.
ERM proteins, which can both bind PIP2 and actin, have thus
an important role in the maintenance of cell shape and po-
larity. They were found to stabilize microvillar structures (63)
and to be essential for motility and maintenance of Schwann
cell polarity (64). In membrane blebs, ezrin was found to be
the ﬁrst protein recruited when bleb expansion ceased (10).
Also, ﬁnally, chromophore assisted light inactivation (micro-
CALI) experiments showed that the selective inactivation of
ezrin induced an immediate reversible cell rounding dem-
onstrating the role of ezrin in deﬁning cell shape (65).
CONCLUSION
Using cosedimentation assays and ﬂuorescence correlation
spectroscopy, we found that ezrin interaction with PIP2-
containing LUVs is speciﬁc with a Kd of ;5 mM, which
would be sufﬁcient for allowing binding of ezrin to PIP2 in the
plasma membrane in vivo. Fluorescently labeled ezrin (ezrin-
Alexa488) was synthesized for the purpose of performing
ﬂuorescence spectroscopy techniques and may be used for
performing subsequent microscopy studies. The interaction
between ezrin and PIP2 was found to be noncooperative.
Finally, by varying ezrin concentration in contact with LUVs
at a ﬁxed lipid concentration, we found that ezrin FERM
domain (;30 nm2) binding to a single PIP2 can block the
access to neighboring PIP2 molecules and thus contributes to
lower the accessible PIP2 concentration. In addition, no evi-
dence exists for a clusterization of PIP2 upon ezrin interaction.
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